A review of bispecific antibodies and antibody constructs in oncology and clinical challengesSuurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot, D. J. A., Sep-2019, In : Pharmacology & Therapeutics. 201, p. 103-119 17 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.
|Number of pages||17|
|Journal||Pharmacology & Therapeutics|
|Early online date||24-Apr-2019|
|Publication status||Published - Sep-2019|
- Bispecific antibody (bsAb), Antibody constructs, Oncology, Cancer immunotherapy, Clinical trials, SINGLE-CHAIN ANTIBODY, MEDULLARY-THYROID CARCINOMA, T-CELLS, MONOCLONAL-ANTIBODIES, BITE ANTIBODY, PHASE-I, PRETARGETED RADIOIMMUNOTHERAPY, ANTITUMOR-ACTIVITY, TARGETED DELIVERY, ANTIGEN-BINDING